Arrowhead Pharmaceuticals Inc (ARWR) — Cash Flow-to-Debt Ratio
Arrowhead Pharmaceuticals Inc (ARWR) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of $20.49 Million could theoretically repay 0% of its total liabilities ($881.88 Million) in one year. See Arrowhead Pharmaceuticals Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arrowhead Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1997–2025)
Historical debt coverage capacity for Arrowhead Pharmaceuticals Inc across 29 annual periods. Also explore ARWR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Arrowhead Pharmaceuticals Inc (1997–2025)
Year-by-year debt coverage analysis for Arrowhead Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Arrowhead Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | $179.55 Million | $947.02 Million | ▲ +138.9% |
| 2024 | -0.49x | $-462.85 Million | $948.74 Million | ▼ -51.7% |
| 2023 | -0.32x | $-153.89 Million | $478.39 Million | ▲ +35.3% |
| 2022 | -0.50x | $-136.13 Million | $273.60 Million | ▼ -187.6% |
| 2021 | 0.57x | $171.22 Million | $301.33 Million | ▲ +136.2% |
| 2020 | -1.57x | $-95.39 Million | $60.72 Million | ▼ -196.1% |
| 2019 | 1.64x | $173.03 Million | $105.81 Million | ▲ +156.7% |
| 2018 | -2.88x | $-47.22 Million | $16.37 Million | ▼ -179.0% |
| 2017 | -1.03x | $-23.94 Million | $23.16 Million | ▲ +46.8% |
| 2016 | -1.94x | $-64.43 Million | $33.15 Million | ▲ +33.0% |
| 2015 | -2.90x | $-65.71 Million | $22.65 Million | ▼ -37.9% |
| 2014 | -2.10x | $-35.42 Million | $16.83 Million | ▼ -28.2% |
| 2013 | -1.64x | $-19.03 Million | $11.59 Million | ▲ +17.4% |
| 2012 | -1.99x | $-15.34 Million | $7.72 Million | ▼ -22.6% |
| 2011 | -1.62x | $-5.39 Million | $3.32 Million | ▲ +9.9% |
| 2010 | -1.80x | $-7.70 Million | $4.28 Million | ▲ +66.5% |
| 2009 | -5.37x | $-15.28 Million | $2.84 Million | ▲ +3.6% |
| 2008 | -5.57x | $-27.58 Million | $4.95 Million | ▲ +20.7% |
| 2007 | -7.03x | $-23.87 Million | $3.40 Million | ▼ -38.7% |
| 2006 | -5.07x | $-14.79 Million | $2.92 Million | ▲ +43.0% |
| 2005 | -8.89x | $-9.10 Million | $1.02 Million | ▼ -164.8% |
| 2004 | -3.36x | $-2.31 Million | $689.70K | ▼ -104.8% |
| 2003 | -1.64x | $-157.60K | $96.18K | ▼ -2399.4% |
| 2002 | -0.07x | $-105.83K | $1.61 Million | ▼ -8.2% |
| 2001 | -0.06x | $-81.81K | $1.35 Million | ▲ +9.7% |
| 2000 | -0.07x | $-80.09K | $1.19 Million | ▼ -105.3% |
| 1999 | -0.03x | $-35.22K | $1.08 Million | ▼ -92.0% |
| 1998 | -0.02x | $-46.15K | $2.71 Million | ▼ -1100.9% |
| 1997 | 0.00x | $4.56K | $2.68 Million | — |